Protect Your Baby from RSV: Nirsevimab Immunisation Now Available

Matilda International Hospital is now offering nirsevimab (marketed as Beyfortus), a new antibody treatment to protect infants and young children from severe Respiratory Syncytial Virus (RSV) disease. Ensure your child is protected during RSV season with this highly effective immunisation.

What is RSV? A Serious Threat to Infants in Hong Kong

Respiratory Syncytial Virus (RSV) is a common and highly contagious virus that infects the respiratory tract. While it often causes mild, cold-like symptoms in adults, it can lead to severe illness in infants and toddlers, for whom it is a leading cause of hospitalisation globally. Their smaller airways and developing immune systems make them particularly vulnerable to complications such as bronchiolitis (inflammation of the small airways in the lungs) and pneumonia.

Almost every child contracts RSV by the age of two. In Hong Kong, the virus is active year-round, and the Centre for Health Protection (CHP) identifies young children as a high-risk group, much like with influenza and COVID-19. This makes prevention a key strategy for protecting their health during this vulnerable stage.

How Nirsevimab Provides Protection

Nirsevimab is not a vaccine; it is a long-acting monoclonal antibody. Instead of prompting the body to create its own antibodies, it delivers them directly to provide immediate protection against RSV.

The antibody works by binding to a protein on the surface of the RSV virus, preventing it from entering respiratory cells and causing infection. Clinical studies have demonstrated that nirsevimab can reduce the risk of RSV-related hospitalisations by over 80%.

This single-dose administration offers a convenient and effective way to provide your child with passive immunity against RSV, offering peace of mind to parents. The protection lasts for at least five months, covering the typical duration of an RSV season.

Who Should Get the Immunisation?

Nirsevimab is suitable for all newborns and high-risk infants, and can be administered alongside routine vaccines. We recommend it for the following children:

• Infants under 12 months: Especially newborns entering their first RSV season.
• High-risk children up to 24 months: For those who are vulnerable to severe RSV in their second season.

Availability and Pricing

Give your child the protection they need against RSV. Beyfortus is now available at the following locations by appointment:

• Inpatients: HK$4,500*
• Outpatient Department (The Peak): HK$5,600
• Matilda Medical Centre (Central): HK$4,500

* Valid until 31 May 2026. Please consult our staff for the latest charges.

Book Your Child's RSV Protection Today

To determine if nirsevimab is right for your child, we recommend consulting with one of our experienced paediatricians. Call us to book:

Outpatient Department 2849 1500
Matilda Medical Centre - Central 2537 8500 

Our dedicated healthcare team at Matilda International Hospital is committed to providing the best preventative care for your family.

Protect your child from RSV today.